Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature

Dermatol Ther. 2019 May;32(3):e12899. doi: 10.1111/dth.12899. Epub 2019 Apr 29.

Abstract

Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis variant refractory to many conventional treatments. We report the successful treatment with secukinumab of a patient with a long history of ACH with marked onychodystrophy with frank pustulosis on the nail bed and with accompanying arthritis. Blockade of the IL-17 receptor A has shown promise in the treatment of psoriatic erythroderma and generalized pustular psoriasis not responsive to conventional treatment. A rapid response was observed in our patient, in both skin lesions and arthritic symptoms, underlining the ability of secukinumab to improve symptoms beyond those of plaque psoriasis.

Keywords: acrodermatitis continua of Hallopeau; psoriasis; psoriatic arthritis; secukinumab.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Acrodermatitis / drug therapy*
  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Humans
  • Interleukin-17 / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal, Humanized
  • Interleukin-17
  • secukinumab